1. Introduction {#sec1}
===============

Antiretroviral Therapy (ART) for the treatment of the human immunodeficiency virus (HIV) infection has been associated with improved survival among HIV infected patients all over the world \[[@B1], [@B2]\]. It is unclear in the current literature whether this progress translates into HIV infected patients admitted to the ICU \[[@B3]--[@B5]\]. No randomized prospective clinical trials have been conducted to guide Highly Active Antiretroviral Therapy (HAART) therapy among HIV patients in the (intensive care unit) ICU. Current evidence from some observational prospective and retrospective studies suggests that early initiation of HAART may be associated with improved outcomes among HIV patients admitted to the ICU \[[@B2], [@B5], [@B6]\].

Admission diagnoses and poor outcomes that were initially attributed to*Pneumocystis jirovecii* pneumonia (PJP) related respiratory failure have altered with the advent of cotrimoxazole prophylaxis \[[@B1], [@B7], [@B8]\]. Acute respiratory failure however has remained a leading cause of ICU admissions due to HIV-associated conditions in high-income countries \[[@B1], [@B7], [@B9]\].

Resource limitations in low-income countries in Africa lead to poor ICU prioritization and utilization. This leads to increased morbidity and mortality from acute illness \[[@B10]--[@B12]\].

HAART was introduced to Uganda in 2001. All patients have access to free HAART since 2007 accordance with local treatment guidelines. HIV care was integrated into national treatment programs in 2010 \[[@B13]\]. As at 2013 the national seroprevalence is currently at 7.4% \[[@B13]\].

Additionally, there are little or no data available regarding outcomes of HIV infected patients admitted to the ICU in HIV endemic low-income countries. Therefore, we conducted a retrospective cohort study of all HIV infected patients who had been admitted to a university teaching hospital in Kampala, Uganda. We sought to identify ICU admission diagnoses, HAART status, clinical characteristics, and outcomes, as well to compare these with and to determine predictors of survival.

2. Methodology {#sec2}
==============

2.1. Study Design and Subjects {#sec2.1}
------------------------------

Upon obtaining a hospital ethical approval and waiver of need for informed consent, we conducted a retrospective cohort study of all HIV infected patients who had been admitted to the intensive care unit of the International Hospital Kampala (IHK) from July 2009 through 2014. IHK is an urban university teaching hospital in Kampala, Uganda, with an 11 bed ICU that can provide both respiratory and renal support services. A combined computerized and manual search of all ICU admissions identified patients with HIV who had been admitted to the ICU. All adult admissions were included.

2.2. Data Collection {#sec2.2}
--------------------

The study team reviewed medical records using standardized pretested forms. Patients who had repeat admissions had their first admission recorded. Demographics were recorded. Admission diagnoses were classified using a predetermined list identical to that used in previous studies \[[@B3], [@B9]\]. Acute Respiratory Distress Syndrome (ARDS) was determined as the need for mechanical ventilation, absence of cardiogenic pulmonary edema with bilateral infiltrates, and a PaO~2~/FiO~2~ ratio of \<200 mmHg. The Berlin definition was not in use during majority of the study period. HAART was categorized as first line, second line, and other regimens based on national treatment guidelines.

Laboratory data within three days of ICU admission (usually within 24 hours) were recorded. Organ failure status (requirement of mechanical ventilator support, renal replacement, or shock), Modified Early Warning Scores (MEWS), and Acute Physiologic and Chronic Health Evaluation (APACHE) II scores on ICU admission were also recorded.

Septic shock status was considered if patients were refractory to IV fluids and needed vasopressors to maintain mean arterial pressure (MAP) \> 65 mmHg. Diagnosis of PJP was based on clinical presentation, radiographic presentations of ground-glass opacities by either computed tomography (CT) or chest radiographs (CXR). There were no facilities to perform bronchoalveolar lavage (BAL). Clinical variables included CD4 count, viral load (plasma HIV RNA if available within 6 months of admission), biochemical and hematological values especially serum albumin, need for vasopressors, and mechanical ventilation, and APACHE II score was calculated. The primary outcome was survival to hospital discharge and secondary outcomes were predictors of mortality. We also measured ICU mortality in all non-HIV patients admitted to the ICU in the study period.

2.3. Statistical Analysis {#sec2.3}
-------------------------

A statistical software package, (StataCorp. 2013.*Stata Statistical Software: Release 13*. College Station, TX: StataCorp LP) was used for analysis. Clinical characteristics are reported as means and medians or numbers and percentages. Continuous data were compared using the Student *t*-test or the Wilcoxon rank sum test, and comparisons of frequencies were made with the *χ* ^2^ test or Fisher\'s exact test. To describe the epidemiology of patients in the current era, we compared patient characteristics according to primary outcome and HAART status. To identify predictors of survival, we compared survivors with nonsurvivors. Unadjusted odds ratios for survival were computed for each candidate variable. Variables with *P* \< 0.20 for the appropriate test were included in model-building procedures in logistic regression. Multivariate logistic regression was used to determine the most penurious variables, using all available data. Statistical significance was predetermined in reference to *P* \< 0.05.

3. Results {#sec3}
==========

3.1. Demographics and Clinical Characteristics {#sec3.1}
----------------------------------------------

During the 5-year study period, there were 1828 patients. Of these, there were 102 HIV admissions for 101 patients. One patient was readmitted following a cardiac arrest and survived to discharge (the readmission was not included in analysis). The average age of patients was 38.13 (±16.05), and females accounted for 53.4% ([Table 1](#tab1){ref-type="table"}). The average length of stay was 4 days (±6.16) ICU/hospital mortality was 57% ([Table 2](#tab2){ref-type="table"}). Mortality in non-HIV ICU patients was 28% over the study period. Average APACHE II score was 24.3 (±7.2) and average MEWS was 6. Majority of patients were already diagnosed HIV patients before admission (89.01%). Of these 54% were on HAART at the time of admission with the majority (75% of those on HAART) being on first-line treatment as per national guidelines at the time ([Table 2](#tab2){ref-type="table"}). Of patients on HAART, 43% had been on treatment for more than 6 months. Most HIV (58.5%) patients had a CD4 count less than 100, while only 4.95% patients had a viral load done at the time of admission ([Table 3](#tab3){ref-type="table"}). Most HIV patients (68%) were on cotrimoxazole prophylaxis at admission. With regard to ICU therapy, 55.4% were on mechanical ventilation, while 36.6% were on vasopressors for septic shock ([Table 4](#tab4){ref-type="table"}). With regard to biochemical tests, the majority had abnormal blood gases (70%), abnormal electrolytes (89.%), hypoalbuminemia (83.1%), elevated urea (72.9%), and bilirubin (54.1%). In addition, majority of patients had moderate to severe anaemia (57.3%).

3.2. Diagnoses of ICU Admissions {#sec3.2}
--------------------------------

Acute respiratory failure (ARF) with ARDS was the commonest cause of admission in 59 of all 101 patients (58.2%, [Table 2](#tab2){ref-type="table"}). Among patients with ARF, PJP and Pulmonary Tuberculosis (PTB) predominated. Respiratory infections were the commonest foci for sepsis. While sepsis was in more than 70% of patients, it was only documented in 21% of admissions as a separate illness. Of these, 36.3% needed vasopressor support for septic shock.

3.3. Comparison of Patients by HAART Status {#sec3.3}
-------------------------------------------

Patients on HAART were significantly older (*P* = 0.01) and predominantly male (*P* = 0.02). HAART naïve patients had significantly higher incidence of toxoplasmosis as an admission diagnosis (*P* = 0.02). HAART naïve patients also had a higher incidence of PJP, although this did not reach statistical significance (*P* = 0.07).

3.4. Predictors of Mortality {#sec3.4}
----------------------------

At univariate analysis, cryptococcal meningitis (CCM), HIV encephalopathy, and ARDS were admission diagnoses associated with mortality. Acidosis, MEWS \> 6, APACHE II, and Glasgow coma score (GCS) \<8 were clinical characteristics associated with mortality ([Table 4](#tab4){ref-type="table"}). Vasopressors and mechanical ventilation were treatment factors associated with mortality (Tables [5](#tab5){ref-type="table"} and [6](#tab6){ref-type="table"}). At multivariate logistic regression analysis, only having mechanical ventilation, high APACHE II and ARDS remained statistically significant ([Table 6](#tab6){ref-type="table"}).

We assessed the goodness of fit of our final model using the Hosmer and Lemeshow statistic and the corresponding chi-square value is 124.41, *P* = 0.258. This showed a good model.

4. Discussion {#sec4}
=============

We conducted this study in a period where there is affordable access to HIV diagnosis and medication in addition to cotrimoxazole prophylaxis in low resource settings. We believe that this study may be the first of its kind looking at HIV in the ICU in an African setting.

The study was conducted in a university teaching hospital with the ability and protocols to provide basic evidence based critical care support such as low tidal volume ventilation; early sepsis recognition and treatment; prone positioning for ARDS, albeit in a low-income country.

The study demographics such as age and sex were similar to that reported in the literature in similar settings \[[@B10]\]. Additionally, this age group is similar to that in which HIV infection is highest in our study setting \[[@B14]\].

The HIV endemicity of our setting is manifested by the high rate of admission (102 in 60 months) for a private medical facility compared to the developed world where admission rates are lower in subsidized care \[[@B1], [@B3], [@B14]\]. The commonest admission diagnoses were similar to that reported in the literature. Acute respiratory failure was the commonest reason for admission and as reported in previous studies, infectious causes such as PJP, PTB, and community acquired pneumonia were predominant causes.

Causes of ICU admissions observed in our study are not different from that observed in studies conducted elsewhere regardless of economic status \[[@B7], [@B15], [@B16]\]. In our study, majority of patients were known HIV patients to the healthcare system. The fact that 11% were undiagnosed HIV patients at ICU admission also points to the efficiency of the national voluntary testing program in our country. More than 50% of all admissions were external referrals. This points to the dearth of ICU beds in the country \[[@B10]\].

Mortality among HIV patients in our setting was higher than in the non-HIV population. A possible explanation is that the severity of illness is worse among HIV patients. Prognostic factors of mortality for HIV patients admitted to the ICU include CD4 count; APACHE II score; features of organ failure (evidenced by the need for mechanical ventilation, renal replacement therapy, and vasopressor support); and hypoalbuminemia. These were identified in studies conducted in North America, Latin America, and Europe \[[@B7], [@B14]--[@B16]\].

More than half the patients presented with CD4 counts \<100 × 10^9^/L. This would also explain the high degree of opportunistic infections seen in these patients. At univariate analysis CD4 was associated with mortality; however after adjusting it was nonsignificant. This was observed in other studies \[[@B2], [@B14], [@B17], [@B18]\]. That viral load testing was not routinely done because of high costs of testing. The median CD4 count of 63 × 10^9^/L was similar to that reported in some literature \[[@B3], [@B19]\]. The threshold for initiating HAART in our country is lower than in higher income settings (our country guidelines recommended starting at a CD4 count of 250 × 10^9^/L or less at the time compared with 500 × 10^9^/L in high-income countries); this may explain the higher severity of illness scores that our patients presented with. However, unlike in the same literature it was not associated with mortality at multivariable analysis.

The APACHE II score in our study was higher than that reported in other studies \[[@B5], [@B14], [@B16]\]. This may also reflect delay in decision to ICU admission or quick deterioration of health. The median APACHE of 25 predicted \>50% mortality. This was true in our study, at bivariate analysis, persisting even after adjusting for multiple variables.

With regard to serum albumin levels, our study did not detect any significant difference or relationship with mortality as was reported in the previous literature \[[@B1]\]. This is possibly due to the low number of patients in whom serum albumin measurement was recorded.

Organ failure was manifest by the need for mechanical ventilation, which was in all patients who presented with respiratory failure. This is similar to other studies where respiratory failure was also the primary reason for admission \[[@B1], [@B3], [@B20]\]. An interesting finding is that all patients who presented with acute respiratory failure got mechanical ventilation and suffered ARDS. They were also 4.5 times more likely to die. The need for mechanical ventilation was associated with mortality at multivariate analysis. Less significant, however, was the need for vasopressor support in patients with septic shock. In this study the foci of sepsis seemed to be of pulmonary origin. This is similar to what has been reported in the literature.

Severe sepsis has been documented as a significant predictor of mortality among HIV patients in other studies \[[@B21]\]. And while sepsis is the most important risk factor for mortality in HIV/AIDS patients admitted to ICUs, affecting short- and longer-term survival \[[@B18]\], we were unable to demonstrate this at multivariate analysis.

HIV/AIDS variables, such as CD4 T-cell count and HIV RNA level, seem to play a secondary role for the prognosis of critically ill HIV/AIDS patients \[[@B4]\]. The mechanisms by which this happens are not clearly understood. A study in Brazil highlighted the occurrence of nosocomial severe infections and the great impact of sepsis on 1- and 6-month survival and confirmed that CD4 the T-cell count, the HIV RNA level, and other HIV/AIDS variables were not predictive of 30-day and 6-month outcomes \[[@B21]\].

While not our primary outcome, our study failed to demonstrate that being on HAART at admission was superior to being HAART naïve. This may have been due to the retrospective nature of our study; low study power; genetic factors; and drug related issues (e.g., bioavailability). However, we noted a weak link between being HAART naïve and development of PJP. Another limitation was that we were unable to document in-ICU HAART initiation due to archival reasons. Early HAART initiation and albumin replacement in HIV infected ICU patients were not standards of care during the study period. There is still the fear that early initiation in PTB, CCM, and Kaposi sarcoma (KS) may predispose patients to immune reconstitution syndrome (IRIS), although it may be argued that the ICU is the best place to manage a patient with IRIS. Demonstrating the impact of HAART on outcomes in our study population has been limited by the short treatment durations majority of patients were under. Additionally, we were unable to document immunologic response and adherence to HAART. Our study had limitations due to its retrospective nature. We were unable to obtain a number of clinical data due to archival reasons.

5. Conclusion {#sec5}
=============

Our study is the first study in Africa to show that ICU mortality due to HIV infection is higher than in higher income countries and higher than that seen in non-HIV ICU patients. A high APACHE II, ARDS, and being on mechanical ventilation are strong predictors of mortality. Our study demonstrated no benefit of HAART status at admission on mortality outcomes.

They authors show their appreciation to the IHK ICU study nurses and clinical teams for participating in the research.

Competing Interests
===================

On behalf of all authors, the corresponding author states that there are no competing interests.

Authors\' Contributions
=======================

Arthur Kwizera and Ian Clarke conceived the study and drafted the manuscript. Cecilia Nantume, Jane Nakibuuka, Catherine Katabira, Lameck Semogerere, Emmanuel Ayebale, and Mary Nabukenya performed the study design and drafted manuscript. Lameck Semogerere, Cecilia Nantume, Mary Nabukenya, Emmanuel Ayebale, and Samuel Kizito performed data collection and manuscript drafting; Arthur Kwizera, Catherine Katabira, and Samuel Kizito performed statistical analysis. All authors read and approved the final manuscript.

###### 

Baseline patient characteristics.

  Variable                        *N*   Categories           Number   Percentage
  ------------------------------- ----- -------------------- -------- ------------
  Sex                             101   Male                 47       46.53
  Female                          54    53.47                         
                                                                      
  Time since diagnosis            101   Known HIV positive   90       89.01
  Made at ICU admission           11    10.99                         
                                                                      
  CD4 range                       101   More than 300        12       11.88
  100 to \<300                    30    29.70                         
  Less than 100                   59    58.42                         
                                                                      
  HAART status                    101   On HAART             56       55.45
  HAART naive                     45    44.55                         
                                                                      
  HAART regimen                   101   1st line             37       36.63
  2nd line                        12    11.88                         
  Not known                       7     6.93                          
  Naïve                           45    44.55                         
                                                                      
  Cotrimoxazole status            101   On cotrimoxazole     69       68.32
                                                                      
  Survival                        101   Discharged           44       43.56
  Died                            57    56.44                         
                                                                      
  Mechanical ventilation          101   Yes                  57       55.44
                                                                      
  Vasopressors for septic shock   101   Yes                  37       36.63

###### 

Univariate analysis of admission diagnoses.

  Admission diagnosis   *N* (%)      Survived     Died         *P* value
  --------------------- ------------ ------------ ------------ -----------
  HIV encephalopathy    3 (2.97)     3 (6.82)     0 (0)        0.079
  Kaposi sarcoma        8 (7.92)     4 (9.09)     4 (7.02)     0.702
  Hypotension           22 (21.78)   7 (15.91)    15 (26.32)   0.209
  Gastrointestinal      5 (4.95)     2 (4.55)     3 (5.26)     0.869
  Multiorgan            28 (27.72)   11 (25.00)   17 (29.82)   0.591
  Liver                 6 (5.94)     2 (4.55)     4 (7.02)     0.694
  Anemia                18 (17.82)   8 (18.18)    10 (17.54)   0.934
  PTB                   18 (17.82)   6 (13.64)    12 (21.05)   0.334
  Toxoplasmosis         14 (3.96)    2 (4.55)     12 (21.05)   0.791
  CCM                   8 (7.92)     6 (13.64)    2 (3.51)     **0.076**
  Meningitis            4 (3.96)     1 (2.27)     3 (5.26)     0.630
  ARF                   59 (58.42)   16 (36.36)   43 (75.44)   **0.000**
  AKI                   20 (19.80)   9 (20.45)    11 (19.30)   0.885
  Sepsis                21 (20.79)   7 (15.91)    14 (24.56)   0.288
  PJP                   21 (20.79)   8 (18.18)    13 (22.81)   0.570

PTB: pulmonary tuberculosis, ARF: acute respiratory failure, AKI: acute kidney injury, PJP: *Pneumocystis jirovecii* pneumonia, and CCM: cryptococcal meningitis.

###### 

Baseline clinical and biochemical characteristics at admission.

  Variable                  Combined   Survived               Died     *P*                                            
  ------------------------- ---------- ---------------------- -------- ------------------ -------- ------------------ ------------
  Age                       101        38.13 ± 16.05          44       37.38 ± 17.23      57       38.70 ± 15.20      0.683
  CD4                       79         139 ± 189              35       160 ± 206          44       123 ± 175          0.393
  Urea                      74         61.30 ± 65.93          36       65.42 ± 80.39      38       57.41 ± 49.32      0.605
  Creatinine                75         2.33 ± 3.05            37       2.21 ± 3.06        38       2.44 ± 3.08        0.750
  Urea: Crea                74         37.98 ± 29.57          36       37.69 ± 25.05      38       38.27 ± 33.63      0.933
  Albumin                   52         21.47 ± 10.77          25       22.34 ± 12.47      27       20.67 ± 9.09       0.582
  Hemoglobin                82         9.61 ± 3.03            40       9.58 ± 3.59        42       9.63 ± 2.42        0.944
  ^*∗*^Metabolic acidosis   **54**     **7.31 ± 0.24**        **25**   **7.43 ± 0.14**    **29**   **7.20 ± 0.26**    **0.0004**
  MEWS                      **101**    **6.35 ± 3.18**        **44**   **4.80 ± 2.87**    **57**   **7.54 ± 2.90**    **0.000**
  APACHE II                 **101**    **24.32 ± 7.23**       **44**   **20.07 ± 5.97**   **57**   **27.60 ± 6.39**   **0.000**
  GCS                       **101**    **10.52** **± 4.63**   **44**   **12.41 ± 3.73**   **57**   **9.07 ± 4.77**    **0.0002**
  Days in ICU               101        4.00 ± 5.58            44       4.57 ± 6.16        57       3.56 ± 5.11        0.372

^*∗*^Metabolic acidosis pH \< 7.15; MEWS: modified early warning score; APACHE: acute physiologic and chronic health evaluation.

###### 

Univariate analysis of key characteristics by survival outcome.

  Variable                Categories            Combined     Survived     Died         *P*
  ----------------------- --------------------- ------------ ------------ ------------ ----------
  Sex                     Male                  47 (46.53)   19 (43.18)   28 (49.12)   0.55
  Female                  54 (53.47)            25 (56.82)   29 (50.88)                
                                                                                       
  CD4 range               Above 300             12 (11.88)   7 (15.91)    5 (8.77)     **0.02**
  100 to 300              30 (29.70)            18 (40.91)   12 (21.05)                
  Below 100               57 (58.42)            19 (43.18)   40 (70.18)                
                                                                                       
  HAART                   On HAART              56 (55.45)   23 (52.27)   33 (57.89)   0.57
  HAART naive             45 (44.55)            21 (47.73)   24 (42.11)                
                                                                                       
  ARV regimen             1st line              37 (36.63)   14 (31.82)   23 (40.35)   0.49
  2nd line                12 (11.88)            7 (15.91)    5 (8.77)                  
  Not known               7 (6.93)              2 (4.55)     5 (8.77)                  
  Naive                   45 (44.55)            21 (47.73)   24 (42.11)                
                                                                                       
  Cotrimoxazole           Yes                   69 (68.32)   30 (68.18)   39 (68.42)   0.98
  No                      32 (31.68)            14 (31.82)   18 (31.58)                
                                                                                       
  Abnormal electrolytes   Yes                   11 (10.89)   6 (13.64)    5 (8.77)     0.52
  No                      90 (89.11)            38 (86.36)   52 (91.23)                
                                                                                       
  Time on HAART           Not known             62 (61.39)   29 (65.91)   33 (57.89)   0.42
  Less than 1 month       15 (14.85)            7 (15.91)    8 (14.04)                 
  1 to 6 months           7 (6.93)              1 (2.27)     6 (10.53)                 
  Beyond 6 months         17 (16.83)            7 (15.91)    10 (17.54)                
                                                                                       
  Septic shock            Yes                   37 (36.63)   7 (15.91)    30 (52.63)   **0.00**
  No                      64 (63.37)            37 (84.09)   27 (47.37)                
                                                                                       
  Ventilator              Yes                   57 (56.44)   12 (27.27)   45 (78.95)   **0.00**
  No                      44 (43.56)            32 (72.73)   12 (21.05)                
                                                                                       
  Urea                    Low (\<8 mg/dL)       1 (1.35)     1 (2.78)     0 (0)        0.58
  Normal                  19 (25.68)            9 (25.00)    10 (26.32)                
  High (\>20 mg/dL)       54 (72.97)            26 (72.22)   28 (73.68)                
                                                                                       
  Creatinine              Low (\<50 *μ*mol/L)   36 (48.00)   20 (54.05)   16 (42.11)   0.41
  Normal                  3 (4.00)              2 (5.41)     1 (2.63)                  
  High (\>150 *μ*mol/L)   36 (48.00)            15 (40.54)   21 (55.26)                
                                                                                       
  Albumin                 Low (\<30 mg/dL)      44 (83.02)   20 (76.92)   24 (88.83)   0.29
  Normal                  9 (16.98)             6 (23.08)    3 (11.11)                 
                                                                                       
  Hemoglobin              Normal                13 (15.85)   7 (17.50)    6 (14.29)    0.85
  Mild anemia             22 (26.83)            10 (25.00)   12 (28.57)                
  Moderate anemia         23 (28.05)            10 (25.00)   13 (30.95)                
  Severe anemia           24 (29.27)            13 (32.50)   11 (26.19)                

###### 

Comparison of patients by HAART status.

  Variable                  Categories           HAART           Naive           *P*
  ------------------------- -------------------- --------------- --------------- --------
  *Mean age (years) ± SD*                        *41.9 ± 15.3*   *33.4 ± 16.0*   *0.01*
                                                                                 
  CD4 ± SD                                       144.5 ± 174.6   133.1 ± 209.7   0.80
                                                                                 
  APACHE ± SD                                    23.7 ± 7.4      25.1 ± 7.0      0.35
                                                                                 
  GCS ± SD                                       10.2 ± 4.5      10.9 ± 4.8      0.48
                                                                                 
  Length of hospital stay                        3.8 ± 6.2       4.2 ± 4.7       0.74
                                                                                 
  Gender                    *Male*               *32 (68.1)*     *15 (31.9)*     *0.02*
  Female                    24 (44.4)            30 (55.6)                       
                                                                                 
  Outcome                   Died                 33 (57.9)       24 (42.1)       0.57
  Survived                  23 (52.3)            21 (47.7)                       
                                                                                 
  Diagnosis                 HIV encephalopathy   2 (66.7)        1 (33.3)        0.69
  No                        54 (55.1)            44 (44.9)                       
  Kaposi sarcoma            6 (75.0)             2 (25.0)        0.25            
  No                        50 (53.8)            43 (46.2)                       
  PTB                       8 (44.4)             10 (55.6)       0.30            
  No PTB                    48 (57.8)            35 (42.2)                       
  *Toxoplasmosis*           *0 (0)*              *14 (100)*      *0.02*          
  No toxo                   56 (57.7)            41 (42.3)                       
  CCM                       3 (37.5)             5 (62.5)        0.29            
  No CCM                    53 (57.0)            40 (43.0)                       
  ARDS                      34 (57.6)            25 (42.4)       0.60            
  No ARDS                   22 (52.4)            20 (47.6)                       
  Sepsis                    12 (57.1)            9 (42.9)        0.86            
  No sepsis                 44 (55.0)            36 (45.0)                       
  AKI                       13 (65.0)            7 (35.0)        0.34            
  No AKI                    43 (53.1)            38 (46.9)                       
  PCP                       8 (38.1)             13 (61.9)       0.07            
  No PCP                    48 (60.0)            32 (40.0)                       

###### 

Multivariate analysis of predictors of mortality.

  Variable                  Categories     OR               95% CI            *P* value      Adjusted OR      95% CI           *P* value
  ------------------------- -------------- ---------------- ----------------- -------------- ---------------- ---------------- -----------
  Interventions             Vasopressors   **0.17**         **0.07--0.44**    0.000^**∗**^   0.51             0.12--2.14       0.351
  Mechanical ventilation    **1.30**       **0.04--0.25**   0.000^**∗**^      **1.14**       **0.09--0.76**   **0.006**        
                                                                                                                               
  GCS                                      **0.84**         **0.76--0.93**    0.001^**∗**^   0.95             0.80--1.13       0.560
                                                                                                                               
  APACHE II                                **1.20**         **1.11--1.30**    0.000^**∗**^   **1.24**         **1.10--1.40**   **0.000**
                                                                                                                               
  MEWS                                     **1.39**         **1.18--1.63**    0.000^**∗**^   1.07             0.86--1.35       0.543
                                                                                                                               
  ^*∗*^Metabolic acidosis                  **0.002**        **0.00--0.15**    0.005^**∗**^                                      
                                                                                                                               
  Disease                   CCM            **4.34**         **0.83--22.67**   0.082          8.15             0.33--202.1      0.200
  ARDS                      **0.14**       **0.05--0.40**   0.000^**∗**^      **4.5**        **1.07--16.7**   **0.039**        

^*∗*^Metabolic acidosis pH \< 7.15; APACHE: acute physiologic and chronic health evaluation.

[^1]: Academic Editor: Robert Boots
